Edition:
United States

Anika Therapeutics Inc (ANIK.OQ)

ANIK.OQ on NASDAQ Stock Exchange Global Select Market

53.39USD
17 Nov 2017
Change (% chg)

$-0.68 (-1.26%)
Prev Close
$54.07
Open
$53.98
Day's High
$54.25
Day's Low
$53.35
Volume
29,000
Avg. Vol
35,927
52-wk High
$60.28
52-wk Low
$41.64

Chart for

About

Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by... (more)

Overall

Beta: 1.48
Market Cap(Mil.): $782.79
Shares Outstanding(Mil.): 14.66
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.35 15.79
EPS (TTM): -- -- --
ROI: -- 15.11 12.01
ROE: -- 16.52 15.91

BRIEF-Anika reports Q3 earnings per share $0.46

* Q3 revenue rose 5 percent to $27.2 million Source text for Eikon: Further company coverage:

Oct 25 2017

BRIEF-Anika completes enrollment in second pivotal phase III trial of cingal

* Anika completes enrollment in second pivotal phase iii trial of cingal for the treatment of knee pain associated with osteoarthritis

Oct 25 2017

BRIEF-Anika announces forthcoming appointment of Thomas Finnerty as chief human resources officer

* Anika announces the forthcoming appointment of Thomas M. Finnerty as chief human resources officer Source text for Eikon: Further company coverage:

Oct 23 2017

BRIEF-Anika Therapeutics announces regulatory approval for Monovisc® in Australia

* Anika announces regulatory approval for Monovisc® in Australia for the treatment of pain associated with osteoarthritis of all synovial joints

Oct 16 2017

BRIEF-Kayne Anderson Rudnick Investment Management Llc reports 11.49 pct passive stake in Anika Therapeutics Inc as of August 08, 2017 - SEC filing

* Kayne anderson rudnick investment management llc reports 11.49 percent passive stake in anika therapeutics inc as of august 08, 2017 - sec filing Source text - (http://bit.ly/2fqZxZ8) Further company coverage:

Aug 08 2017

BRIEF-Anika announces appointment of Joseph Darling as president

* Anika therapeutics - co's ceo dr. Charles h. Sherwood who served as president, plans to transition role to darling, while continuing tenure as ceo Source text for Eikon: Further company coverage:

Jul 27 2017

BRIEF-Anika announces regulatory approval for Monovisc in India

* Anika announces regulatory approval for Monovisc in India for the treatment of pain associated with osteoarthritis of all synovial joints Source text for Eikon: Further company coverage:

Jul 24 2017

BRIEF-Anika announces $5 mln milestone payment from U.S. commercial sales of Monovisc

* Anika announces $5 million milestone payment from U.S. Commercial sales of Monovisc

Jul 17 2017

BRIEF-Anika Therapeutics expects to complete supplemental phase III trial of CINGAL in 2018

* Anika announces first patient enrolled in supplemental phase III trial of CINGAL for the treatment of knee pain associated with osteoarthritis

May 25 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $138.00 -0.87
Novartis AG (NOVN.S) CHF83.30 +0.90
Pfizer Inc. (PFE.N) $35.37 -0.19
Roche Holding Ltd. (ROG.S) CHF230.10 +1.10
Roche Holding Ltd. (RO.S) CHF233.30 +1.30
Merck & Co., Inc. (MRK.N) $55.20 +0.03
Bayer AG (BAYGn.DE) €107.55 -0.35
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €75.43 -0.54
Abbott Laboratories (ABT.N) $55.56 +0.02

Earnings vs. Estimates